First quarter fiscal year 2027
Filed Aug 20, 2026Virtuix Reports First Quarter Fiscal Year 2027 Results as Omni One Orders Increase 150% Following Meta Launch
New Omni One orders increased 72% year-over-year, gross profit increased 29%, and gross margin expanded to 30% from 17%, but net sales declined 26%, operating expenses rose 86%, net loss widened to ($7.2) million, adjusted EBITDA loss widened, and cash declined to $7.4 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net salesGAAP | $0.8 million | – | 26% decrease |
| SalesGAAP | $767,300 | – | 26% decrease |
| New orders for Omni One systemsother | increased 72% | – | increased 72% |
| New orders for Omni One systems since launch of Omni One for Questother | increased approximately 150% | – | increased approximately 150% since the launch of Omni One for Quest compared to the same period last year |
| Cost of goods soldGAAP | $540,142 | – | – |
| Gross profitGAAP | $227,158 | – | increased 29% |
| Gross marginGAAP | 30% | – | expanded to 30% from 17% |
| Selling expensesGAAP | $738,978 | – | – |
| General and administrative expensesGAAP | $3,080,778 | – | – |
| Research and development expensesGAAP | $309,375 | – | – |
| Total operating expensesGAAP | $4.1 million | – | increased by $1.9 million, or 86% |
| Loss from operationsGAAP | ($3,901,973) | – | – |
| Total other expense, netGAAP | ($3.2 million) | – | – |
| Interest expenseGAAP | ($2,539,592) | – | – |
| Financing expenseGAAP | ($584,150) | – | – |
| Loss on extinguishment of debtGAAP | ($431,224) | – | – |
| Provision for income taxGAAP | $49,391 | – | – |
| Net lossGAAP | ($7.2) million | – | – |
| Net lossGAAP | ($7,170,566) | – | – |
| Net loss per basic and diluted shareGAAP | ($0.22) | – | narrowed from ($0.28) to ($0.22) per share |
| Weighted average common shares outstanding, basic and dilutedGAAP | 32,787,960 | – | – |
| Adjusted EBITDA lossnon-GAAP | ($3.1) million | – | – |
| Adjusted EBITDAnon-GAAP | ($3,072,832) | – | – |
| Cash used in operating activitiesGAAP | ($3,294,829) | – | – |
| Cash used in investing activitiesGAAP | ($11,247) | – | – |
| Cash provided by financing activitiesGAAP | $1,278,657 | – | – |
| Net decrease in cashGAAP | ($2,027,419) | – | – |
| Cash and cash equivalentsGAAP | $7,443,869 | – | – |
| Current portion of notes payable, net of discount and unamortized deferred loan costsGAAP | $9,658,998 | – | – |
| Notes payable, net of discount and unamortized deferred loan costsGAAP | $1,039,518 | – | – |
| Total liabilitiesGAAP | $15,660,981 | – | – |
| Total stockholders' (deficit) equityGAAP | ($3,080,495) | – | – |
What drove it
- Current-quarter revenue was generated from newly acquired customers, while the prior-year period benefited from fulfillment of the final batch of legacy Omni One preorder backlog accumulated since August 2023.
- New orders for Omni One systems increased 72% year-over-year, with approximately 150% growth since the launch of Omni One for Quest.
- Gross-margin expansion primarily reflected the higher selling price of the complete Omni One system compared with units delivered in the prior-year period.
- The company delivered an Omni One system to the Pennsylvania Air National Guard, its first deployment with the Air National Guard.
- Virtuix sold its first Omni One Enterprise system to Tesla, Inc. for the Optimus humanoid robot division's teleoperation use.
- Virtuix was awarded U.S. Air Force funding under Phase I of the AFWERX SBIR program for its Virtual Terrain Walk platform.
Concerns
- Net sales declined 26% to $0.8 million from $1.0 million.
- Total operating expenses increased by $1.9 million, or 86%, to $4.1 million, driven primarily by a non-cash $0.7 million increase in stock compensation expense and a $1.2 million increase in public-company professional services fees.
- Net loss widened to ($7.2) million from ($2.3) million, primarily reflecting $4.0 million of non-cash charges and higher operating expenses.
- Adjusted EBITDA loss widened to ($3.1) million from ($1.9) million.
- Interest expense was ($2,539,592), including $2,052,255 of non-cash amortization of debt discount related to financing arrangements.
- The filing cites limited cash runway and substantial doubt regarding the company's ability to continue as a going concern, as disclosed in its latest Quarterly Report on Form 10-Q.
- The company identifies the need for additional capital and the ability to meet convertible note and other debt obligations when due as risks.
What to watch
- Whether the reported 72% year-over-year growth in new Omni One orders converts into accelerating revenue growth.
- Delivery of the U.S. Marine Corps Infantry Fireteam Trainer pilot system to Quantico, VA, expected in the fourth calendar quarter of 2026.
- Results of the U.S. Marine Corps evaluation of LeadTech's Counter-UAS Personnel Trainer and potential AFWERX SBIR Phase II and Phase III funding.
- Progress on acquisition opportunities in defense training and simulation involving companies with annual revenues in the $10 million to $50 million range.
- Potential joint marketing and bundling opportunities under the Meta collaboration.
- Execution of enterprise deployments with Tesla, NASA's year-long MMEA study beginning in 2027, and Sirica Therapeutics' plan to establish approximately 100 treatment centers nationwide.
Balance sheet and cash flow
- Cash and cash equivalents totaled $7.4 million as of June 30, 2026, compared to $9.5 million as of March 31, 2026.
- Cash used in operating activities was ($3,294,829), compared to ($1,491,122) in the prior-year period.
- Cash used in investing activities was ($11,247), compared to ($3,496) in the prior-year period.
- Cash provided by financing activities was $1,278,657, including $1,380,000 from warrants exercised and ($96,600) of equity issuance costs.
- Current portion of notes payable, net of discount and unamortized deferred loan costs, was $9,658,998 as of June 30, 2026.
- Total liabilities were $15,660,981 and total stockholders' (deficit) equity was ($3,080,495) as of June 30, 2026.
Analysis
Virtuix reported a split first quarter. Net sales declined 26% to $0.8 million from $1.0 million, but management attributed the prior-year revenue to fulfillment of the final batch of legacy preorder backlog accumulated since August 2023. The current quarter's revenue came from newly acquired customers, while new orders for Omni One systems rose 72% year-over-year and approximately 150% since the launch of Omni One for Quest. Management stated that similar order momentum continued into the current quarter.
Product economics improved despite the lower reported sales base. Gross profit rose 29% to $227,158 from $176,077, and gross margin expanded to 30% from 17%. The company attributed the improvement primarily to a higher selling price for the complete Omni One system than the price of units delivered in the prior-year quarter. The filing does not report revenue by consumer, defense, enterprise, or healthcare segment, so the financial contribution from the new Tesla, Air National Guard, Sirica, and other deployments cannot be quantified.
Costs and financing charges drove substantially wider losses. Operating expenses increased 86% to $4.1 million, led by a non-cash $0.7 million increase in stock compensation expense and a $1.2 million increase in public-company professional-services costs. Total other expense was $3.2 million, including $2.5 million of interest expense and non-cash amortization of debt discount associated with convertible notes. GAAP net loss widened to ($7.2) million from ($2.3) million, while adjusted EBITDA loss widened to ($3.1) million from ($1.9) million. Basic and diluted net loss per share nevertheless narrowed to ($0.22) from ($0.28), alongside weighted-average shares of 32,787,960 versus 8,259,732.
Cash and financing remain central considerations. Cash and cash equivalents were $7.4 million at June 30, 2026, down from $9.5 million at March 31, 2026. The company used ($3.3) million in operating activities and received $1.3 million from financing activities, including $1.4 million from warrants exercised. Current notes payable, net of discount and unamortized deferred loan costs, were $9.7 million, and stockholders' equity moved to a ($3.1) million deficit from $1.1 million as of March 31, 2026. The filing explicitly identifies limited cash runway, substantial doubt regarding going concern, additional-capital needs, and debt obligations as risks.
Operationally, Virtuix is broadening Omni One's use cases across defense, robotics, healthcare, and consumer markets. The company cited its first Tesla Optimus sale, a first Air National Guard deployment, U.S. Air Force Phase I AFWERX SBIR funding, progress on the Marine Corps Infantry Fireteam Trainer, NASA MMEA selection for a study beginning in 2027, and two systems shipped to Sirica Therapeutics. Management also said its special committee is reviewing defense-sector acquisitions. No formal financial guidance was provided, leaving conversion of higher orders into revenue, defense-program progression, financing capacity, and acquisition execution as the principal disclosed items to monitor.
Management, verbatim
The first quarter of fiscal 2027 was one of the strongest commercial quarters in our Company’s recent history.
Jan Goetgeluk, CEO of Virtuix
While reported revenue was lower year-over-year, that comparison reflects the completion of our legacy preorder backlog: revenue in the prior-year period was driven largely by the fulfillment of the final batch of the large backlog of Omni One orders accumulated since the start of our preorder period in August 2023, whereas revenues this quarter resulted from sales to newly acquired customers.
Jan Goetgeluk, CEO of Virtuix
Our unit economics also continued to improve. Gross profit increased 29% year-over-year and gross margin expanded to 30% from 17%, primarily reflecting the higher selling price of the complete Omni One system in the first quarter of fiscal 2027 compared to the price of units delivered in the prior-year period.
Jan Goetgeluk, CEO of Virtuix
Not in the filing
stated, not guessed- Formal quantified financial guidance for revenue, gross margin, operating expenses, tax rate, earnings, cash flow, or capital expenditures
- Previous-quarter outlook for comparison with actual results
- Revenue by reportable segment or by consumer, defense, enterprise, and healthcare end market
- Non-GAAP earnings per share
- Free cash flow
- Capital-return program information, including share repurchases or dividends
- Tax rate
- Total debt stated as a single consolidated figure
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.